Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the substituents are as defined herein.
Type:
Grant
Filed:
July 13, 2006
Date of Patent:
June 8, 2010
Assignee:
Takeda San Diego, Inc.
Inventors:
Jerome C. Bressi, Anthony R. Gangloff, Lily Kwok
Abstract: Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
Type:
Grant
Filed:
October 14, 2005
Date of Patent:
May 11, 2010
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Qing Dong, David J. Hosfield, Bheema R. Paraselli, Nicholas Scorah, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.